NEW YORK, NY--(Marketwire - Jan 12, 2012) - Several small cap biotechnology stocks are looking to make a splash in the highly lucrative cancer drug market this year. According to a recent press release issued by Denver-based Cannabis Science, global cancer drug sales are expected to grow at a compounded annual rate of 12 to 15 percent, reaching $75 to $80 billion by 2012. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Generex Biotechnology Corporation (OTCBB: [ GNBT ]) and Cannabis Science Inc. (OTCBB: [ CBIS ]). Access to the full company reports can be found at:

[ www.fivestarequities.com/GNBT ]

[ www.fivestarequities.com/CBIS ]

Cannabis Science, Inc. is a development stage company engaged in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. Last week the company reported the continuing successful progress by two patients who have been topically self-administering Cannabis Science extracts for Squamous Cell Carcinoma Cancer and Skin Cancer.

Cannabis Science recently issued its fiscal 2012 earnings guidance. The company says sales for 2012 are forecasted to be $6,846,000, while arguing that the company's revenues have "the potential to increase to $65,740,000 in 2014."

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.fivestarequities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. The Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer. Positive interim results from the ongoing Phase 2 study of AE37 were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in December. The company says that final Phase 2 results are expected at some point this year.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ www.fivestarequities.com/disclaimer ]